The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.

Humans Male Prostate / pathology Prostatectomy Prostatic Neoplasms, Castration-Resistant

Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 07 06 2021
revised: 26 10 2021
accepted: 31 01 2022
pubmed: 9 2 2022
medline: 6 4 2022
entrez: 8 2 2022
Statut: ppublish

Résumé

The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations. Three separate TMA sets were built that differ by purpose and disease state. The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases. The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation. This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.

Sections du résumé

BACKGROUND
The need to better understand the molecular underpinnings of the heterogeneous outcomes of patients with prostate cancer is a pressing global problem and a key research priority for Movember. To address this, the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project constructed a set of unique and richly annotated tissue microarrays (TMA) from prostate cancer samples obtained from multiple institutions across several global locations.
METHODS
Three separate TMA sets were built that differ by purpose and disease state.
RESULTS
The intended use of TMA1 (Primary Matched LN) is to validate biomarkers that help determine which clinically localized prostate cancers with associated lymph node metastasis have a high risk of progression to lethal castration-resistant metastatic disease, and to compare molecular properties of high-risk index lesions within the prostate to regional lymph node metastases resected at the time of prostatectomy. TMA2 (Pre vs. Post ADT) was designed to address questions regarding risk of castration-resistant prostate cancer (CRPC) and response to suppression of the androgen receptor/androgen axis, and characterization of the castration-resistant phenotype. TMA3 (CRPC Met Heterogeneity)'s intended use is to assess the heterogeneity of molecular markers across different anatomic sites in lethal prostate cancer metastases.
CONCLUSIONS
The GAP1-UTMA project has succeeded in combining a large set of tissue specimens from 501 patients with prostate cancer with rich clinical annotation.
IMPACT
This resource is now available to the prostate cancer community as a tool for biomarker validation to address important unanswered clinical questions around disease progression and response to treatment.

Identifiants

DOI: 10.1158/1055-9965.EPI-21-0600 PMID: 35131885 PMC: PMC9381093
pubmed: 35131885
pii: 1055-9965.EPI-21-0600
doi: 10.1158/1055-9965.EPI-21-0600
pmc: PMC9381093
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

715-727

Subventions

Organisme : NCI NIH HHS
ID : P50 CA058236
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097186
Pays : United States

Informations de copyright

©2022 The Authors; Published by the American Association for Cancer Research.

Références

PLoS One. 2011;6(11):e27970
pubmed: 22114732
Transl Androl Urol. 2013 Sep;2(3):122-36
pubmed: 26816735
Prostate. 2014 Jan;74(1):61-9
pubmed: 24115205
Lancet. 2014 Dec 6;384(9959):2027-35
pubmed: 25108889
Eur Urol. 2014 Jun;65(6):1046-55
pubmed: 24439788
Eur Urol Focus. 2016 Jun;2(2):180-188
pubmed: 27617307
Hum Pathol. 2003 Jul;34(7):646-53
pubmed: 12874759
Cancer Res. 2004 Dec 15;64(24):9209-16
pubmed: 15604294
Clin Cancer Res. 2011 Oct 15;17(20):6563-73
pubmed: 21878536
Am J Clin Pathol. 2017 Nov 02;148(5):398-415
pubmed: 29106457
Clin Cancer Res. 2015 Oct 15;21(20):4698-708
pubmed: 26071481
Arch Pathol Lab Med. 2019 Mar;143(3):338-348
pubmed: 30295067
Am J Surg Pathol. 2020 Jul;44(7):e15-e29
pubmed: 32044806
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Pathol. 2013 Jul;230(3):291-7
pubmed: 23420560
Clin Exp Metastasis. 2016 Mar;33(3):239-48
pubmed: 26667932
Prostate. 2004 Nov 1;61(3):215-27
pubmed: 15368473
Cardiovasc Pathol. 2010 May-Jun;19(3):136-46
pubmed: 19211265
J Pathol. 2003 Aug;200(5):610-9
pubmed: 12898597
J Natl Cancer Inst. 2015 Nov 27;108(2):
pubmed: 26615022
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Cancer. 2006 Aug 1;107(3):439-50
pubmed: 16795064
JAMA. 1999 May 5;281(17):1591-7
pubmed: 10235151
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Cancer Res. 2006 Nov 15;66(22):10683-90
pubmed: 17108105
Mod Pathol. 2003 Jan;16(1):79-84
pubmed: 12527717
Mod Pathol. 2004 Jul;17(7):790-7
pubmed: 15073602
Eur Urol. 2014 Jan;65(1):20-5
pubmed: 23619390
Mod Pathol. 2016 Dec;29(12):1565-1574
pubmed: 27562498
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398

Auteurs

Véronique Ouellet (V)

Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.
ORCID: 0000-0003-1854-7082

Andrew Erickson (A)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
Department of Pathology, Helsinki and Uusimaa Hospital District and Medicum, University of Helsinki, Helsinki, Finland.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Kathy Wiley (K)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Colm Morrissey (C)

Department of Urology, University of Washington, Seattle, Washington.

Viktor Berge (V)

Department of Urology, Oslo University Hospital, Oslo, Norway.

Carlos S Moreno (CS)

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
Winship Cancer Institute of Emory University, Atlanta, Georgia.
ORCID: 0000-0002-5582-0028

Kristin Austlid Tasken (KA)

Institute of Cancer Research, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
ORCID: 0000-0001-5530-4915

Dominique Trudel (D)

Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.
Department of Pathology and Cellular Biology, Université de Montréal, Montreal, Canada.
ORCID: 0000-0001-9820-1772

Lawrence D True (LD)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.

Michael S Lewis (MS)

West Los Angeles Veterans Affairs Medical Center and Departments of Pathology and Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

Aud Svindland (A)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Pathology, Oslo University Hospital, Oslo, Norway.

Onur Ertunc (O)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Suleyman Demirel University, Department of Pathology, Training and Research Hospital East Campus, Isparta, Turkey.
ORCID: 0000-0002-4159-1711

Igor Damasceno Vidal (ID)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Adeboye O Osunkoya (AO)

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
Winship Cancer Institute of Emory University, Atlanta, Georgia.
ORCID: 0000-0001-5712-8134

Tracy Jones (T)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

G Steven Bova (GS)

Faculty of Medicine and Health Technology, Prostate Cancer Research Center, Tampere University and Tays Cancer Center, Tampere, Finland.
ORCID: 0000-0003-1639-3104

Tarja Lamminen (T)

Institute of Biomedicine, University of Turku, Turku, Finland.

Ariel H Achtman (AH)

Movember, Melbourne, Australia.

Mark Buzza (M)

Movember, Melbourne, Australia.

Michelle M Kouspou (MM)

Movember, Melbourne, Australia.

Steven A Bigler (SA)

Department of Pathology, Mississippi Baptist Medical Center, Jackson, Mississippi.

Xinchun Zhou (X)

Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi.

Stephen J Freedland (SJ)

Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California.
Section of Urology, Durham VA Medical Center, Durham, North Carolina.

Anne-Marie Mes-Masson (AM)

Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.
Department of Medicine, Université de Montréal, Montreal, Canada.
ORCID: 0000-0002-6498-266X

Isla P Garraway (IP)

Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, California.
Division of Urology, Greater Los Angeles VA Healthcare System, Los Angeles, California.

Bruce J Trock (BJ)

Department of Urology and Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
ORCID: 0000-0003-3529-9295

Pekka Taimen (P)

Institute of Biomedicine, University of Turku, Turku, Finland.
Department of Pathology, Turku University Hospital, Turku, Finland.
ORCID: 0000-0001-8849-4604

Fred Saad (F)

Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.
Department of Surgery, Université de Montréal, Montreal, Canada.

Tuomas Mirtti (T)

HUS Diagnostic Center, Department of Pathology, HUS Helsinki University Hospital, Helsinki, Finland.
Medicum and Research Program In Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0003-0455-9891

Beatrice S Knudsen (BS)

Digital and Computational Pathology, University of Utah, Salt Lake City, Utah.
ORCID: 0000-0002-7589-7591

Angelo M De Marzo (AM)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Urology and Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
ORCID: 0000-0003-4847-5307

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Movember Global Action Plan 1 (GAP1):...
Recherchemedicale.com › Tissus › Glandes exocrines › Prostate › The Movember Global Action Plan 1 (GAP1):...
Recherchemedicale.com › Procédures de chirurgie opératoire › Procédures de chirurgie urogénitale › Procédures de chirurgie urologique › Procédures de chirurgie urologique masculine › Prostatectomie › The Movember Global Action Plan 1 (GAP1):...
Recherchemedicale.com › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › The Movember Global Action Plan 1 (GAP1):...